The Outliers: Ammonia N13 and Voluven
This article was originally published in Pharmaceutical Approvals Monthly
In 2007, both CDER and CBER included in their final count of novel approvals products that had been cleared under the 505(b)(2) pathway - which is an expedited type of application that relies on sharing data with similar products that are on the market (and thus making products approved as 505(b)(2) by definition not unique).
You may also be interested in...
FDA only approved one biologic with mass-market potential in 2007, a seasonal flu vaccine. Nearly half of the new biologics approved - three of seven - will not be available commercially. Another three are for orphan indications
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011